Ranbaxy Laboratories has got sanction from the US Food and Drug Administration (USFDA) to produce and market Hydrocodone Bitartrate and Acetaminophen Tablets USP, 75 mg/750 mg, 10 mg/500 mg, 5 mg/500 mg, and 10 mg/325 mg strengths.

The USFDA determined that these medications have the same curative result as that of the reference listed drugs as follows. 10 mg/325 mg Norco Tablets of Watson Pharmaceuticals Inc., 5 mg/500 mg Vicodin Tablets, and 7.5 mg/750 mg Vicodin ES Tablets both of Abbott Laboratories, and 10 mg/500 mg Lortab Tablets of UCB Inc.

Total yearly market sales for Hydrocodone Bitartrate and Acetaminophen pills stood at USD 390.6 million. These tabs are suggested to get relief of moderate to moderately severe pain.

Jim Meehan, vice president of sales and marketing for RPI “Hydrocodone Bitartrate and Acetaminophen Tablets are indicated for the relief of moderate to moderately severe pain and Ranbaxy is pleased to receive final FDA approval for multiple strengths of this product. These approvals further expand our product portfolio of affordable generic alternatives and will be launched in a November 2007 time period to all classes of trade.”

Ranbaxy Pharmaceuticals (RPI) is established in Jacksonville, Florida, USA. This wholly owned subsidiary is engaged in the sale and delivery of generic as well as well-known treatment products in the U.S. healthcare system.